{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:00:51Z","timestamp":1787497251911,"version":"build-2736575974"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"N.K."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hidradenitis suppurativa (HS) is characterized by increased interleukin (IL)-17A\/C\/F. Two open-label trials of brodalumab, an IL-17 receptor antagonist, have been completed, with 8 of 10 patients receiving brodalumab fortnightly and 10 of 10 patients receiving brodalumab weekly achieving 75% Hidradenitis Suppurativa Clinical Response. All patients were biologic \u2018experienced\u2019 but were not reported to have failed biologic treatment. We report outcomes for eight patients with HS who had failed at least one biologic, treated with brodalumab 210\u2005mg fortnightly, to provide real-world evidence. Four of eight patients remain on brodalumab, with a\u00a0mean treatment duration of\u00a011.3\u2005months. All patients who remain on brodalumab subjectively report continued treatment efficacy. The mean Dermatology Life Quality Index reduced from 20.6 to 16.8 at week 16. All patients required concurrent antibiotics due to flares. Brodalumab may be effective in patients who have previously failed multiple biologics, but efficacy in our real-world study falls short of the two open-label trials. This may reflect severe treatment-resistant disease. In the absence of further licensed treatments for HS, brodalumab may be a good option following adalimumab failure.<\/jats:p>","DOI":"10.1093\/ced\/llad130","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T06:11:34Z","timestamp":1680675094000},"page":"790-792","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of hidradenitis suppurativa with brodalumab in\u00a0biologic treatment failures: experiences from a specialty\u00a0clinic"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-3462","authenticated-orcid":false,"given":"Niamh","family":"Kearney","sequence":"first","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s University Hospital , Dublin , Ireland"},{"name":"UCD School of Medicine, University College Dublin , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s University Hospital , Dublin , Ireland"},{"name":"UCD School of Medicine, University College Dublin , Dublin , Ireland"},{"name":"UCD Charles Institute of Dermatology, University College Dublin , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s University Hospital , Dublin , Ireland"},{"name":"UCD School of Medicine, University College Dublin , Dublin , Ireland"},{"name":"UCD Charles Institute of Dermatology, University College Dublin , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"2023101015305364900_llad130-B1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2023101015305364900_llad130-B2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023101015305364900_llad130-B3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jamadermatol.2017.0432","article-title":"Interventions for hidradenitis suppurativa: updated summary of an original Cochrane Review","volume":"153","author":"Ingram","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2023101015305364900_llad130-B4","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.12688\/f1000research.21216.1","article-title":"Case report: treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches","volume":"8","author":"Tampouratzi","year":"2019","journal-title":"F1000Res"},{"key":"2023101015305364900_llad130-B5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/1346-8138.15807","article-title":"Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: a possible involvement of Th17 across the spectrum of both diseases","volume":"48","author":"Yoshida","year":"2021","journal-title":"J Dermatol"},{"key":"2023101015305364900_llad130-B6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ijd.14792","article-title":"Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure","volume":"59","author":"Arenbergerova","year":"2020","journal-title":"Int J Dermatol"},{"key":"2023101015305364900_llad130-B7","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study","volume":"83","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023101015305364900_llad130-B8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.19478","article-title":"Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study","volume":"184","author":"Frew","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023101015305364900_llad130-B9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad130\/50213488\/llad130.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/7\/790\/51988547\/llad130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/7\/790\/51988547\/llad130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T11:34:21Z","timestamp":1696937661000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/7\/790\/7107420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":9,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4,5]]},"published-print":{"date-parts":[[2023,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad130","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,4,5]]}}}